After reading these articles, you should be able to…

Lurasidone (Latuda) was approved by the FDA for schizophrenia in October 2010 and is the 10th atypical antipsychotic in our toolbox. The key question is: does lurasidone have any advantages over existing agents, or is it just another “me-too” drug?

In what ways, if any, are cognitive problem a distinct feature of schizophrenia? And how can we use this information to guide treatment?

Check out this table for details on all of the atypical antipsychotics you commonly prescribe.

Information in this table is on the June CME Test, so please read it with the rest of this issue's content.

Dr. Carpenter, you are a member of the DSM-5 work group that is considering risk syndrome for first psychosis, or what is now called “attenuated psychosis syndrome” as a new diagnosis in the manual.

A combination of clinical lore and some studies have led many psychiatrists to believe that it is crucial to screen depressed patients for subtle signs of “bipolarity.”

After reading these articles, you should be able to…

Let’s face it, dealing with side effects is not high on the list of “things we like most about psychiatry."

Do SSRIs and SNRIs cause bleeding? Several review articles have been published about it, and patients are beginning to ask us about it. What’s the scoop?

Use this scale to keep better track of your patients' side effects.